Gerard Silvestri, MD
Pulmonary Disease · Charleston, SCNPI 1417922865
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $219,236 of the $254,116 with a category attached, or 86.3%. 19 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 32.8% of the total. Reporting peaked in 2020 at $74,564 and has fallen 65.8% since, to $25,485 in 2025. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $1165.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$83K
- Olympus Corporation Of The Americas$42K
- AstraZeneca$39K
- Olympus America Inc.$30K
- Gyrus ACMI, Inc.$18K
- Johnson & Johnson$8K
- plus $33K from 13 others
Across 61 payments — averaging $14,813 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$468K
- Johnson & Johnson$117K
- Olympus Corporation$104K
- Olympus Corporation Of The Americas$91K
- Veran Medical Technologies, Inc.$70K
- Boston Scientific$22K
- plus $33K from 5 others
What the payments were for
- Consulting fees$219,23686%
- Speaking & faculty fees$17,6337%
- Travel & lodging$7,4163%
- Food & beverage$2,3711%
- Education$7,4603%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 11 | $83,473 |
| Olympus Corporation Of The Americas | 54 | $42,020 |
| AstraZeneca | 38 | $38,834 |
| Olympus America Inc. | 40 | $29,516 |
| Gyrus ACMI, Inc. | 26 | $18,480 |
| Johnson & Johnson | 5 | $8,448 |
| Boehringer Ingelheim International GmbH | 3 | $6,510 |
| Astrazeneca UK Limited | 2 | $6,237 |
| Olympus Corporation | 17 | $4,894 |
| Sanofi | 3 | $4,033 |
| Olympus Medical Systems Corporation | 5 | $3,460 |
| Exact Sciences | 2 | $2,640 |
| Boehringer Ingelheim Canada Ltd.ltee | 1 | $2,000 |
| Eli Lilly | 1 | $1,600 |
| Spiration, Inc. | 2 | $880 |
| Medtronic | 2 | $585 |
| ERBE USA Inc | 1 | $198 |
| Intuitive Surgical | 2 | $172 |
| Regeneron Healthcare Solutions, Inc. | 3 | $137 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spin$58,719
- Olympus Bronchoscopes$26,168
- EVES EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE$17,240
- SPiN Thoracic Navigation System, 120V, 60Hz$16,062
- IMFINZI$14,672
- TAGRISSO$8,654
- MONARCH$7,573
- OFEV$6,510
- BF Videoscopes$3,080
- Cologuard Collection Kit$2,640
- EVIS EXERA II ULTRASONIC BRONCHOFIBERVIDEOSCOPE$2,200
- SPiN Vision Video Processor$1,760
- Monarch Platform$800
- Olympus Respiratory Accessories$748
- ERBE$198
- ILLUMISITE$100
How this compares
$254,116 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $10,777 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,226 |
| Wixela InhubFluticasone Propion/Salmeterol | 18 | $2,663 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $909 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Charleston
- Patrick FlumeCharleston$418K
- Denise Gabrielle SeseCharleston$51K
- Timothy WhelanCharleston$41K
- Marc JudsonCharleston$28K
- John HugginsCharleston$18K
- John CoxCharleston$16K
- Adam FoxCharleston$13K
- Michael SpandorferCharleston$12K
- Rachana KrishnaCharleston$9K
- Abhijit RavalAnderson$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.